Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180470 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL27970625 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL27612145 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL29879550 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL8517654 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL3730643 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL4169780 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL751283 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL8652229 | 1.00 | SPHK1 (0.60) | SPHK1CYP2D6LMNAGMNNPOLB | |
| SCHEMBL27243094 | 0.97 | SPHK1 (0.58) | SPHK1CYP2D6LMNAGMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573886-B | Method for producing cyclic alpha-ketols from cyclic alpha-ketoenols | 巴斯夫欧洲公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3180311-B1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-10017464-B2 | Process for preparing cyclic alpha-keto alcohols from cyclic alpha-keto enols | BASF SE (DE) | 2018-07-10 | — | — | US | disclosed |
| US-10017465-B2 | Method for producing astaxanthin from astacin | BASF SE (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170233338-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170217884-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | BASF SE (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3180310-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | BASF SE (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-3180311-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023772-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | BASF SE (DE) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023732-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | BASF SE (DE) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233338-A1 | METHOD FOR PRODUCING ASTAXANTHIN FROM ASTACIN | ADH1B, ADH5, ADH7 | SPHK1 620/4885CYP2D6 519/4885LMNA 2917/4885 |
| US-10017465-B2 | Method for producing astaxanthin from astacin | ADH1B, ADH5, ADH7 | SPHK1 620/4885CYP2D6 519/4885LMNA 2917/4885 |
| US-20170217884-A1 | PROCESS FOR PREPARING CYCLIC ALPHA-KETO ALCOHOLS FROM CYCLIC ALPHA-KETO ENOLS | AKR1C3, AKR1C2, AKR1A1 | SPHK1 407/4885CYP2D6 539/4885LMNA 1180/4885 |
| US-10017464-B2 | Process for preparing cyclic alpha-keto alcohols from cyclic alpha-keto enols | AKR1C3, AKR1C2, AKR1A1 | SPHK1 407/4885CYP2D6 539/4885LMNA 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.